Stock MLAB MESA LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Mesa Laboratories, Inc.

Equities

MLAB

US59064R1095

Real-time Estimate Cboe BZX
Other stock markets
 02:25:11 2024-04-29 pm EDT 		5-day change 1st Jan Change
106.8 USD +3.45% Intraday chart for Mesa Laboratories, Inc. +3.82% +1.34%
Apr. 08 Mesa Laboratories, Inc. Amends and Restates Its Senior Secured Credit Agreement with Syndicate of Banks Led by JPMorgan Chase Bank, N.A CI
Apr. 05 Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company has insufficient levels of profitability.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
MESA LABORATORIES, INC. Stock Mesa Laboratories, Inc.
+1.34% 557M
C
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.79% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.97% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.48% 66.9B
A
DEXCOM, INC. Stock DexCom, Inc.
+0.65% 49.45B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.56% 48B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.61% 26.48B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.91% 26.25B
A-
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MLAB Stock
  4. Ratings Mesa Laboratories, Inc.